HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CRBM 0244

an anti-inflammatory agent; structure in first source

Also Known As:

CRBM-0244; CRBM0244

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cantin, André M: 1 article (08/2011)
2.	Fortin, Samuel: 1 article (08/2011)
3.	Morin, Caroline: 1 article (08/2011)
4.	Rousseau, Eric: 1 article (08/2011)

Related Diseases

1.	Respiratory Hypersensitivity 08/01/2011 - "Hence, CRBM-0244 treatment prevents airway hyperresponsiveness, Ca(2+) hypersensitivity, and the overexpression of CPI-17 in lung tissue. " 08/01/2011 - "The effects of a newly synthesized docosahexaenoic acid (DHA) derivative, CRBM-0244, on lung inflammation and airway hyperresponsiveness were determined in an in vitro model of TNF-α-stimulated human bronchi and in an in vivo model of allergic asthma. "
2.	Pneumonia (Pneumonitis) 08/01/2011 - "The effects of a newly synthesized docosahexaenoic acid (DHA) derivative, CRBM-0244, on lung inflammation and airway hyperresponsiveness were determined in an in vitro model of TNF-α-stimulated human bronchi and in an in vivo model of allergic asthma. "
3.	Inflammation (Inflammations) 08/01/2011 - "Together, these findings provide key evidence regarding the mode of action of CRBM-0244 in the lung, and point to new therapeutic strategies for modulating inflammation in patients with asthma." 08/01/2011 - "Furthermore, the presence of specialized enzymes such as 5-lipoxygenase and 15-lipoxygenase in the lung may convert CRBM-0244 into active mediators, leading to the resolution of inflammation. "
4.	Hypersensitivity (Allergy) 08/01/2011 - "Hence, CRBM-0244 treatment prevents airway hyperresponsiveness, Ca(2+) hypersensitivity, and the overexpression of CPI-17 in lung tissue. "
5.	Asthma (Bronchial Asthma) 08/01/2011 - "The in vivo anti-inflammatory properties of CRBM-0244 were also investigated in a guinea pig model of allergic asthma. " 08/01/2011 - "Together, these findings provide key evidence regarding the mode of action of CRBM-0244 in the lung, and point to new therapeutic strategies for modulating inflammation in patients with asthma." 08/01/2011 - "The effects of a newly synthesized docosahexaenoic acid (DHA) derivative, CRBM-0244, on lung inflammation and airway hyperresponsiveness were determined in an in vitro model of TNF-α-stimulated human bronchi and in an in vivo model of allergic asthma. "

Related Drugs and Biologics

1.	Enzymes
2.	Docosahexaenoic Acids
3.	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
4.	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)